Walleye Capital’s Altimmune ALT Stock Holding History

Walleye Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.3K	Sell	10,800 -53,600	-83%	-$228K	﹤0.01%	3988
2025 Q4	$232K	Sell	64,400 -24,000	-27%	-$105K	﹤0.01%	3466
2025 Q3	$333K	Buy	88,400 +65,000	+278%	+$251K	﹤0.01%	2926
2025 Q2	$90.6K	Buy	+23,400	New	+$127K	﹤0.01%	3820
2025 Q1	–	Sell	-13,600	Closed	-$98.1K	–	4192
2024 Q4	$98.1K	Buy	+13,600	New	+$104K	﹤0.01%	4153
2024 Q3	–	Sell	-11,400	Closed	-$75.8K	–	5219
2024 Q2	$75.8K	Buy	11,400 +7,900	+226%	+$58.3K	﹤0.01%	4818
2024 Q1	$35.6K	Buy	+3,500	New	+$35.6K	﹤0.01%	4780
2023 Q2	–	Sell	-200	Closed	-$844	–	4265
2023 Q1	$844	Buy	+200	New	+$2.38K	﹤0.01%	3835
2022 Q4	–	Sell	-15,700	Closed	-$200K	–	3145
2022 Q3	$200K	Buy	+15,700	New	+$232K	﹤0.01%	2119

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital's ALT Position: Q1 2026 in Review

Walleye Capital reduced its Altimmune (ALT) stake by 100% in Q1 2026, selling an estimated $279K and leaving 2 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #4313.

Walleye Capital first reported a position in ALT in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.58M in Q2 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Walleye Capital held 2 shares of Altimmune worth $6 as of Q1 2026.
Walleye Capital sold 65,663 Altimmune shares in Q1 2026, an estimated $279K.
Altimmune made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4313 holding.
Walleye Capital first reported a position in Altimmune in Q4 2021 and has held it in 12 quarters since.
Walleye Capital's Altimmune position peaked at $1.58M in Q2 2022.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.